US pharmaceutical giant Pfizer has applied to the Ministry of Health, Labor and Welfare for approval of a new coronavirus vaccine for the Omicron strain.
The target is 12 years old and over, and it is the first application in Japan for a vaccine for the Omicron strain.
According to Pfizer's announcement, it applied for approval to the Ministry of Health, Labor and Welfare on the 8th, among the Omicron strains, "BA.1" that spread around the beginning of this year and "Bivalent It is a type of vaccine called "vaccine", and the target age is 12 years and older.
It contains the artificial genetic material `` messenger RNA '' that corresponds to each virus, and evokes the function of immunity by creating a protrusion `` spike protein '' on the surface of the new coronavirus in the body.
In June this year, Pfizer announced that in a clinical trial involving more than 1,200 people aged 56 and over, this vaccine had a higher number of viruses corresponding to "BA.1" than the conventional vaccine. It has been announced that the value of neutralizing antibodies that suppress the action has increased significantly.
Pfizer submitted an application for approval to the EMA (European Medicines Agency) last month for this vaccine.